← All companies

SYRE

Spyre Therapeutics, Inc.

SYRE Nasdaq Pharmaceutical Preparations EDGAR ↗

$94.93

-6.57 -6.47%

Key statistics

from XBRL data in SEC filings

Market cap

$8.24B

Revenue (TTM)

$0.00

Net income (TTM)

-$179M

EPS (TTM)

$13.76

P/E ratio

6.9

Dividend yield

—

Free cash flow

—

Cash

$97.2M

Total assets

$764M

Gross margin

—

52-week range

$14.51 – $105.09

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Regulation FD disclosure; Other events Jun 15, 2026 8-K Other events Jun 1, 2026 8-K Director or officer change; Shareholder vote results May 29, 2026 8-K Results of operations (earnings release) May 5, 2026 10-Q Quarter ended 2026-03-31 May 5, 2026 8-K Entered a material agreement Apr 16, 2026 8-K Results of operations (earnings release); Other events Apr 13, 2026 8-K Regulation FD disclosure; Other events Apr 13, 2026 8-K Results of operations (earnings release) Feb 19, 2026 10-K Fiscal year ended 2025-12-31 Feb 19, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Nov 4, 2025 10-Q Quarter ended 2025-09-30 Nov 4, 2025 8-K Entered a material agreement Oct 15, 2025 8-K Results of operations (earnings release) Oct 14, 2025 8-K Results of operations (earnings release) Aug 5, 2025 10-Q Quarter ended 2025-06-30 Aug 5, 2025 8-K Regulation FD disclosure; Other events Jun 17, 2025 8-K Shareholder vote results Jun 2, 2025 8-K Results of operations (earnings release) May 8, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Changed accountants Mar 6, 2025 8-K Results of operations (earnings release) Feb 27, 2025 10-K Fiscal year ended 2024-12-31 Feb 27, 2025 8-K Results of operations (earnings release); Other events Jan 13, 2025 8-K Entered a material agreement Nov 19, 2024 10-Q/A Quarter ended 2024-09-30 Nov 18, 2024 10-Q/A Quarter ended 2024-06-30 Nov 18, 2024 10-Q/A Quarter ended 2024-03-31 Nov 18, 2024 10-K/A Fiscal year ended 2023-12-31 Nov 18, 2024 8-K Previously issued financials not reliable; Other events Nov 18, 2024 8-K Regulation FD disclosure; Other events Nov 12, 2024 8-K Results of operations (earnings release) Nov 7, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Entered a material agreement; Regulation FD disclosure; Other events Oct 15, 2024 8-K/A Other events Aug 8, 2024 8-K Results of operations (earnings release) Aug 7, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Regulation FD disclosure May 30, 2024 8-K Entered a material agreement; Director or officer change; Amended charter or bylaws; Shareholder vote results; Regulation FD disclosure May 15, 2024